The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Abstract
The RET gene encodes a receptor tyrosine kinase that is expressed in neural crest-derived cell lineages. The RET receptor plays a crucial role in regulating cell proliferation, migration, differentiation, and survival through embryogenesis. Activating mutations in RET lead to the development of several inherited and noninherited diseases. Germline point mutations are found in the cancer syndromes multiple endocrine neoplasia (MEN) type 2, including MEN 2A and 2B, and familial medullary thyroid carcinoma. These syndromes are autosomal dominantly inherited. The identification of mutations associated with these syndromes has led to genetic testing to identify patients at risk for MEN 2 and familial medullary thyroid carcinoma and subsequent implementation of prophylactic thyroidectomy in mutation carriers. In addition, more than 10 somatic rearrangements of RET have been identified from papillary thyroid carcinomas. These mutations, as those found in MEN 2, induce oncogenic activation of the RET tyrosine kinase domain via different mechanisms, making RET an excellent candidate for the design of molecular targeted therapy. Recently, various kinds of therapeutic approaches, such as tyrosine kinase inhibition, gene therapy with dominant negative RET mutants, monoclonal antibodies against oncogene products, and nuclease-resistant aptamers that recognize and inhibit RET have been developed. The use of these strategies in preclinical models has provided evidence that RET is indeed a potential target for selective cancer therapy. However, a clinically useful therapeutic option for treating patients with RET-associated cancer is still not available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedNeutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
Cerchia, L., Ducongé, F., Pestourie, C., Boulay, J., Aissouni, Y., Gombert, K., Tavitian, B., de Franciscis, V., & Libri, D. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030123 · Cited by 246
RetractedSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
The GDNF family: Signalling, biological functions and therapeutic value
Airaksinen, M. S., & Saarma, M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn812 · Cited by 1,828
Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., & Pachnis, V. (1994) · Nature · doi:10.1038/367380a0 · Cited by 1,614
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Hirschsprung disease, associated syndromes and genetics: a review
Amiel, J., Sproat-Emison, E., Garcia-Barcelo, M., Lantieri, F., Burzynski, G., Borrego, S., Pelet, A., Arnold, S., Miao, X., Griseri, P., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.053959 · Cited by 1,206
Self-citationJing, S., Wen, D., Yu, Y., Holst, P. L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81311-2 · Cited by 1,174
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Self-citationThe role of focal-adhesion kinase in cancer — a new therapeutic opportunity
McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J., Brunton, V. G., & Frame, M. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1647 · Cited by 1,039
Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor
Schlessinger, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00966-2 · Cited by 993
Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Ports, G., Fusco, A., & Vecchiot, G. (1990) · Cell · doi:10.1016/0092-8674(90)90659-3 · Cited by 959
Activation of a novel human transforming gene, ret, by DNA rearrangement
Takahashi, M., Ritz, J., & Cooper, G. M. (1985) · Cell · doi:10.1016/0092-8674(85)90115-1 · Cited by 854
Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B
Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. (1995) · Science · doi:10.1126/science.7824936 · Cited by 841
Expression of the c-ret proto-oncogene during mouse embryogenesis
Pachnis, V., Mankoo, B., & Costantini, F. (1993) · Development · doi:10.1242/dev.119.4.1005 · Cited by 837
Carlson, K. M., Dou, S., Chi, D., Scavarda, N., Toshima, K., Jackson, C. E., Wells, S. A., Goodfellow, P. J., & Donis-Keller, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1579 · Cited by 600
Carlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., & Santoro, M. M. (2002) · PubMed · Cited by 569
Early Malignant Progression of Hereditary Medullary Thyroid Cancer
Machens, A., Niccoli-Sire, P., Hoegel, J., Frank-Raue, K., van Vroonhoven, T. J., Roeher, H.-D., Wahl, R. A., Lamesch, P., Raue, F., Conte-Devolx, B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa012915 · Cited by 545
Eng, C., SmIth, D. P., MullIgan, L. M., Nagal, M. A., Healey, C. S., Ponder, M. A., Gardner, E., Scheumann, G. F. W., Jackson, C. E., Tunnacllffe, A., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.2.237 · Cited by 537
Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526
RET/PTC Rearrangement in Thyroid Tumors
Nikiforov, Y. E. (2002) · Endocrine Pathology · doi:10.1385/ep:13:1:03 · Cited by 489
Hirschsprung disease, associated syndromes, and genetics: a review
Amiel, J., & Lyonnet, S. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.729 · Cited by 479
GDNF Family Neurotrophic Factor Signaling: Four Masters, One Servant?
Airaksinen, M. S., Titievsky, A., & Saarma, M. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0754 · Cited by 477
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
The GDNF family ligands and receptors — implications for neural development
Baloh, R. H., Enomoto, H., Johnson, E. M., & Milbrandt, J. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(99)00048-3 · Cited by 475
Proximity of Chromosomal Loci That Participate in Radiation-Induced Rearrangements in Human Cells
Nikiforova, M. N., Stringer, J. R., Blough, R., Medvedovic, M., Fagin, J. A., & Nikiforov, Y. E. (2000) · Science · doi:10.1126/science.290.5489.138 · Cited by 468
RET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
Lips, C., Landsvater, R. M., Hoppener, J., Geerdink, R. A., Blijham, G., van Veen, J. M. J.-S., van Gils, A., de Wit, M. J., Zewald, R. A., Berends, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311302 · Cited by 454
Self-citationThe GDNF/RET signaling pathway and human diseases
Takahashi, M. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00012-0 · Cited by 446
A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10
Mathew, C. G. P., Chin, K. S., Easton, D. F., Thorpe, K., Carter, C., Liou, G. I., Fong, S.-L., Bridges, C. D. B., Haak, H., Kruseman, A. C. N., et al. (1987) · Nature · doi:10.1038/328527a0 · Cited by 440
Lipid rafts in neuronal signaling and function
Tsui-Pierchala, B. A., Encinas, M., Milbrandt, J., & Johnson, E. M. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02215-4 · Cited by 409
Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A
Skinner, M. A., Moley, J. A., Dilley, W. G., Owzar, K., DeBenedetti, M. K., & Wells, S. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043999 · Cited by 381
Post-prenylation-processing enzymes as new targets in oncogenesis
Winter-Vann, A. M., & Casey, P. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1612 · Cited by 357
Mechanism of Activation of the ret Proto-oncogene by Multiple Endocrine Neoplasia 2A Mutations
Asai, N., Iwashita, T., Matsuyama, M., & Takahashi, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1613 · Cited by 340
Traxler, P., Allegrini, P. R., Brandt, R., Brueggen, J., Cozens, R., Fabbro, D., Grosios, K., Lane, H. A., McSheehy, P., Mestan, J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3681 · Cited by 320
Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas
Jhiang, S. M. (1996) · Endocrinology · doi:10.1210/en.137.1.375 · Cited by 314
Tansey, M. G., Baloh, R. H., Milbrandt, J., & Johnson, E. M. (2000) · Neuron · doi:10.1016/s0896-6273(00)81064-8 · Cited by 308
Tallini, G., Santoro, M. M., Helie, M., Carlomagno, F., Salvatore, G., Chiappetta, G., Carcangiu, M. L., & Fusco, A. (1998) · PubMed · Cited by 302
The RET proto-oncogene in human cancers
Jhiang, S. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203857 · Cited by 298
Overexpression and overactivation of Akt in thyroid carcinoma.
Ringel, M. D., Hayre, N., Saito, J., Saunier, B., Schuppert, F., Burch, H., Bernet, V., Burman, K. D., Kohn, L. D., & Saji, M. (2001) · PubMed · Cited by 297
The RET receptor: function in development and dysfunction in congenital malformation
Manié, S., Santoro, M., Fusco, A., & Billaud, M. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02420-9 · Cited by 291
Paratcha, G., Ledda, F., Baars, L., Coulpier, M., Besset, V., Anders, J., Scott, R., & Ibáñez, C. F. (2001) · Neuron · doi:10.1016/s0896-6273(01)00188-x · Cited by 290
Somatic mutations in the RET proto‐oncogene in sporadic medullary thyroid carcinoma
Marsh, D. J., Learoyd, D. L., Andrew, S. D., Krishnan, L., Pojer, R., Richardson, A., Delbridge, L., Eng, C., & Robinson, B. G. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.681503.x · Cited by 279
Distinct Multiple RET/PTC Gene Rearrangements in Multifocal Papillary Thyroid Neoplasia1
Sugg, S. L., Ezzat, S., Rosen, I. B., Freeman, J. L., & Asa, S. L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.11.5271 · Cited by 273
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity
Sun, J., Blaskovich, M. A., Jove, R., Livingston, S. K., Coppola, D., & Sebti, S. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208470 · Cited by 263
Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., Billaud, M., & Santoro, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207810 · Cited by 258
The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
Powell, D. J., Russell, J. P., Nibu, K., Li, G., Rhee, E. N., Liao, M., Goldstein, M., Keane, W. M., Santoro, M. M., Fusco, A., et al. (1998) · PubMed · Cited by 255
Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis
de Graaff, E., Srinivas, S., Kilkenny, C., D'Agati, V., Mankoo, B. S., Costantini, F., & Pachnis, V. (2001) · Genes & Development · doi:10.1101/gad.205001 · Cited by 251
Pheochromocytoma: The expanding genetic differential diagnosis.
Bryant, J., Farmer, J., Kessler, L. J., Townsend, R. R., & Nathanson, K. L. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg024 · Cited by 250
The control of cell motility and epithelial morphogenesis by Jun kinases
Xia, Y., & Karin, M. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2003.12.005 · Cited by 242
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522758 · Cited by 242
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis
Hansford, J. R., & Mulligan, L. M. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.11.817 · Cited by 241
Gimm, O. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3902 · Cited by 237
Santoro, M., Chiappetta, G., Cerrato, A., Salvatore, D., Zhang, L., Manzo, G., Picone, A., Portella, G., Santelli, G., Vecchio, G., et al. (1996) · PubMed · Cited by 234
Berndt, I., Reuter, M., Saller, B., Frank-Raue, K., Groth, P., Grußendorf, M., Raue, F., Ritter, M. M., & Höppner, W. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4619 · Cited by 229
Antisense therapy in oncology: new hope for an old idea?
Tamm, I., Dörken, B., & Hartmann, G. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05629-x · Cited by 229
Antagonists of protein–protein interactions
Cochran, A. G. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00106-x · Cited by 228
Role of JNK in Tumor Development
(2003) · Cell Cycle · doi:10.4161/cc.2.3.388 · Cited by 225
RET Oncogene Activation in Papillary Thyroid Carcinoma
Tallini, G., Asa, S. L., & Fuller, G. N. (2001) · Advances in Anatomic Pathology · doi:10.1097/00125480-200111000-00005 · Cited by 223
Segouffin-Cariou, C., & Billaud, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3568 · Cited by 223
Hayashi, H., Ichihara, M., Iwashita, T., Murakami, H., Shimono, Y., Kawai, K., Kurokawa, K., Murakumo, Y., Imai, T., Funahashi, H., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203799 · Cited by 223
Eng, C., & Mulligan, L. M. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)9:2<97::aid-humu1>3.0.co;2-m · Cited by 212
Vasko, V, Saji, M., Hardy, E., Kruhlak, M., Larin, A., Savchenko, V, Miyakawa, M., Isozaki, O., Murakami, H., Tsushima, T., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.015339 · Cited by 211
Distinct Multiple RET/PTC Gene Rearrangements in Multifocal Papillary Thyroid Neoplasia
Sugg, S. L. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.11.4116 · Cited by 210
STAT signaling in the pathogenesis and treatment of leukemias
Lin, T. S., Mahajan, S., & Frank, D. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203486 · Cited by 205
Activation of Tyrosine Kinases in Cancer
Vlahovic, G., & Crawford, J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-531 · Cited by 202
Miller, K. D., Trigo, J. M., Wheeler, C., Barge, A., Rowbottom, J., Sledge, G., & Baselga, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1923 · Cited by 198
Ichihara, M. (2004) · Cancer Letters · doi:10.1016/s0304-3835(03)00456-7 · Cited by 197
Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188
Yu, T., Scully, S., Yu, Y., Fox, G. M., Jing, S., & Zhou, R. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-12-04684.1998 · Cited by 188
Asai, N., Murakami, H., Iwashita, T., & Takahashi, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17644 · Cited by 184
Grimm, J., Sachs, M., Britsch, S., Di Cesare, S., Schwarz-Romond, T., Alitalo, K., & Birchmeier, W. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200102032 · Cited by 182
Bongarzone, I., Vigneri, P. G., Mariani, L., Collini, P., Pilotti, S., & Pierotti, M. A. (1998) · PubMed · Cited by 178
Encinas, M., Tansey, M. G., Tsui-Pierchala, B. A., Comella, J. X., Milbrandt, J., & Johnson, E. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01464.2001 · Cited by 169
In vitro irradiation is able to cause RET oncogene rearrangement.
Ito, T., Seyama, T., Iwamoto, K. S., Hayashi, T., Mizuno, T., Tsuyama, N., Dohi, K., Nakamura, N., & Akiyama, M. (1993) · PubMed · Cited by 163
Anders, J., Kjær, S., & Ibáñez, C. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104968200 · Cited by 163
Cancer after nuclear fallout: lessons from the Chernobyl accident
Williams, D. (2002) · Nature reviews. Cancer · doi:10.1038/nrc845 · Cited by 154
Fagin, J. A. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05895 · Cited by 154
Brooks, A. S., Bertoli‐Avella, A. M., Burzynski, G. M., Breedveld, G. J., Osinga, J., Boven, L. G., Hurst, J. A., Mancini, G. M. S., Lequin, M. H., de Coo, I. F. M., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/431244 · Cited by 152
Self-citationBorrego, S., Sáez, M. E., Ruiz, A., Gimm, O., López-Alonso, M., Antiñolo, G., & Eng, C. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.10.771 · Cited by 146
Liu, X., Vega, Q. C., Decker, R. A., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5309 · Cited by 145
Miyauchi, A., Futami, H., Hai, N., et al. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00658.x · Cited by 145
Blaskovich, M. A., Lin, Q., Delarue, F. L., Sun, J., Park, H. S., Coppola, D., Hamilton, A. D., & Sebti, S. M. (2000) · Nature Biotechnology · doi:10.1038/80257 · Cited by 143
Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis
Links, T. P., van Tol, K. M., Jager, P. L., Plukker, J. T. M., Piers, D. A., Boezen, H. M., Dullaart, R. P. F., de Vries, E. G. E., & Sluiter, W. J. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00892 · Cited by 142
Self-citationThyroid cancer risk to children calculated
Jacob, P., Goulko, G., Heidenreich, W., Ia, L., Kairo, I. A., Tronko, M. D., Ti, B., Kenigsberg, J., Buglova, E. E., Drozdovitch, V., et al. (1998) · Nature · doi:10.1038/32076 · Cited by 140
Schilling, T., B�rck, J., Sinn, H., Clemens, A., Otto, H. F., H�ppner, W., Herfarth, C. H., Ziegler, R., Schwab, M., & Raue, F. (2001) · International Journal of Cancer · Cited by 139
Melillo, R. M., Santoro, M. M., Ong, S. H., Billaud, M., Fusco, A., Hadari, Y. R., Schlessinger, J., & Lax, I. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4177-4187.2001 · Cited by 138
Heinlein, C. A., Ting, H., Yeh, S., & Chang, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16147 · Cited by 135
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.
Carlomagno, F., Vitagliano, D., Guida, T., Napolitano, M., Vecchio, G., Fusco, A., Gazit, A., Levitzki, A., & Santoro, M. M. (2002) · PubMed · Cited by 135
RET activation by germline MEN2A and MEN2B mutations.
Borrello, M. G., Smith, D. P., Pasini, B., Bongarzone, I., Greco, A., Lorenzo, M. J., Arighi, E., Miranda, C., Eng, C., & Alberti, L. (1995) · PubMed · Cited by 134
Novel Mechanism of Regulation of Rac Activity and Lamellipodia Formation by RET Tyrosine Kinase
Fukuda, T., Kiuchi, K., & Takahashi, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200643200 · Cited by 134
TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS
Tibes, R., Trent, J. C., & Kurzrock, R. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100124 · Cited by 133
Tsui-Pierchala, B. A., Milbrandt, J., & Johnson, E. (2002) · Neuron · doi:10.1016/s0896-6273(01)00585-2 · Cited by 133
Chiariello, M., Visconti, R., Carlomagno, F., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201778 · Cited by 131
Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma1
Cheung, C. C., Ezzat, S., Ramyar, L., Freeman, J. L., & Asa, S. L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.2.6404 · Cited by 130
Fagin, J. A. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.5.0838 · Cited by 130
Coordinated Activation of Autophosphorylation Sites in the RET Receptor Tyrosine Kinase
Coulpier, M., Anders, J., & Ibáñez, C. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107992200 · Cited by 128
Santoro, M., Melillo, R. M., Grieco, M., Berlingieri, M. T., Vecchio, G., & Fusco, A. (1993) · PubMed · Cited by 126
Ledda, F., Paratcha, G., & Ibáñez, C. F. (2002) · Neuron · doi:10.1016/s0896-6273(02)01002-4 · Cited by 122
Iwashita, T., Kato, M., Murakami, H., Asai, N., Ishiguro, Y., Ito, S., Iwata, Y., Kawai, K., Asai, M., Kurokawa, K., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202742 · Cited by 120
Basolo, F., Giannini, R., Monaco, C., Melillo, R. M., Carlomagno, F., Pancrazi, M., Salvatore, G., Chiappetta, G., Pacini, F., Elisei, R., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64368-4 · Cited by 117
RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors
Santoro, M., Papotti, M. G., Chiappetta, G., Garcia-Rostan, G., Volante, M., Johnson, C., Camp, R. L., Pentimalli, F., Monaco, C., Herrero, A., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.1.8174 · Cited by 117
Transmembrane Peptides as Inhibitors of ErbB Receptor Signaling
Bennasroune, A., Fickova, M., Gardin, A., Dirrig‐Grosch, S., Aunis, D., Crémel, G., & Hubert, P. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-10-0753 · Cited by 115
Cuccuru, G., Lanzi, C., Cassinelli, G., Pratesi, G., Tortoreto, M., Petrangolini, G., Seregni, E. C., Martinetti, A., Laccabue, D., Zanchi, C., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh184 · Cited by 115
Tyrosine 981, a Novel Ret Autophosphorylation Site, Binds c-Src to Mediate Neuronal Survival
Encinas, M., Crowder, R. J., Milbrandt, J., & Johnson, E. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400505200 · Cited by 113
Cohen, M. S., Hussain, H. B., & Moley, J. F. (2002) · Surgery · doi:10.1067/msy.2002.128562 · Cited by 113
Carlomagno, F., Vitagliano, D., Guida, T., Basolo, F., Castellone, M. D., Melillo, R. M., Fusco, A., & Santoro, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021278 · Cited by 113
Kurokawa, K., Iwashita, T., Murakami, H., Hayashi, H., Kawai, K., & Takahashi, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204290 · Cited by 111
Iwashita, T., Asai, N., Murakami, H., Matsuyama, M., & Takahashi, M. (1996) · PubMed · Cited by 110
Chiappetta, G., Toti, P., Cetta, F., Giuliano, A., Pentimalli, F., Amendola, I., Lazzi, S., Monaco, M., Mazzuchelli, L., Tosi, P., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.1.8180 · Cited by 108
Identification of RET Autophosphorylation Sites by Mass Spectrometry
Kawamoto, Y., Takeda, K., Okuno, Y., Yamakawa, Y., Ito, Y., Taguchi, R., Kato, M., Suzuki, H., Takahashi, M., & Nakashima, I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312600200 · Cited by 107
MEN2A-RET-induced cellular transformation by activation of STAT3
Schuringa, J. J., Wojtachnio, K., Hagens, W. I., Vellenga, E., Buys, C. H. C. M., Hofstra, R. M. W., & Kruijer, W. (2001) · Oncogene · doi:10.1038/sj.onc.1204715 · Cited by 106
Self-citationStudying the genetics of Hirschsprung's disease: unraveling an oligogenic disorder
Brooks, A., Oostra, B. A., & Hofstra, R. M. W. (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00319.x · Cited by 106
Self-citationBorrego, S., Wright, F. A., Fernández, R. M., Williams, N., López-Alonso, M., Davuluri, R. V., Antiñolo, G., & Eng, C. (2003) · The American Journal of Human Genetics · doi:10.1086/345466 · Cited by 101
Menko, F. H., van der Luijt, R. B., de Valk, I. A. J., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.1.8136 · Cited by 99
Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells.
Takahashi, M., Buma, Y., & Taniguchi, M. (1991) · PubMed · Cited by 99
Shc and Enigma Are Both Required for Mitogenic Signaling by Ret/ptc2
Durick, K., Gill, G. N., & Taylor, S. S. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.2298 · Cited by 97
Murakami, H., Iwashita, T., Asai, N., Shimono, Y., Iwata, Y., Kawai, K., & Takahashi, M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1186 · Cited by 96
Niccoli, P., Murat, A., Baudin, É., Henry, J. F., Proye, C. A. G., Bigorgne, J., Bständig, B., Modigliani, E., Morange, S., Schlumberger, M. J., et al. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410468 · Cited by 96
Plaza-Menacho, I., Koster, R., van der Sloot, A. M., Quax, W. J., Osinga, J., van der Sluis, T., Hollema, H., Burzynski, G. M., Gimm, O., Buys, C. H. C. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2363 · Cited by 94
Self-citationTreatment of medullary thyroid carcinoma: an update.
Orlandi, F., Caraci, P., Mussa, A., Saggiorato, E., Pancani, G., & Angeli, A. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080135 · Cited by 94
Strock, C. J., Park, J., Rosen, M. A., Dionne, C. A., Ruggeri, B., Jones‐Bolin, S., Denmeade, S. R., Ball, D. W., & Nelkin, B. D. (2003) · PubMed · Cited by 94
Kuntzen, C., Sonuc, N., Toni, E. N. D., Opelz, C., Mucha, S. R., Gerbes, A. L., & Eichhorst, S. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2618 · Cited by 92
Machens, A., Holzhausen, H.-J., Thanh, P. N., & Dralle, H. (2003) · Surgery · doi:10.1067/s0039-6060(03)00157-0 · Cited by 87
Characterization of the ret proto-oncogene products expressed in mouse L cells.
Takahashi, M., Asai, N., Iwashita, T., Isomura, T., Miyazaki, K., & Matsuyama, M. (1993) · PubMed · Cited by 86
Pelicci, G., Troglio, F., Bodini, A., Melillo, R. M., Pettirossi, V., Coda, L., Giuseppe, A. D., Santoro, M. M., & Pelicci, P. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7351-7363.2002 · Cited by 85
RET proto-oncogene point mutations in sporadic neuroendocrine tumors
Komminoth, P., Roth, J., Muletta-Feurer, S., Saremaslani, P., Seelentag, W. K. F., & Heitz, P. U. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.6.2041 · Cited by 83
Tsao, P., Wei, S., Su, Y.-N., Chou, H., Chen, C., & Hsieh, W. (2005) · PEDIATRICS · doi:10.1542/peds.2004-2240 · Cited by 82
Guarino, V., Faviana, P., Salvatore, G., Castellone, M. D., Cirafici, A. M., Falco, V. D., Celetti, A., Giannini, R., Basolo, F., Melillo, R. M., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0271 · Cited by 80
Murakami, H., Iwashita, T., Asai, N., Iwata, Y., Narumiya, S., & Takahashi, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202514 · Cited by 80
Cebrián, A., Lesueur, F., Martin, S., Leyland, J., Ahmed, S., Luccarini, C., Smith, P. L., Luben, R., Whittaker, J., Pharoah, P. D. P., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2449 · Cited by 79
Characterization of Gene Expression Induced by RET with MEN2A or MEN2B Mutation
Watanabe, T., Ichihara, M., HASHIMOTO, M., Shimono, K., Shimoyama, Y., Nagasaka, T., Murakumo, Y., Murakami, H., Sugiura, H., Iwata, H., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64176-4 · Cited by 77
Schuetz, G., Rosário, M., Grimm, J., Boeckers, T. M., Gundelfinger, E. D., & Birchmeier, W. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200404108 · Cited by 76
Meric‐Bernstam, F. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.10.013 · Cited by 76
MET Receptor Tyrosine Kinase Sequence Alterations in Differentiated Thyroid Carcinoma
Wasenius, V.-M., Hemmer, S., Karjalainen‐Lindsberg, M., Nupponen, N. N., Franssila, K., & Joensuu, H. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000156103.37756.e2 · Cited by 75
Role of Dok1 in Cell Signaling Mediated by RET Tyrosine Kinase
Murakami, H., Yamamura, Y., Shimono, Y., Kawai, K., Kurokawa, K., & Takahashi, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202336200 · Cited by 73
Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma
Cheung, C. C. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.878 · Cited by 73
Salvatore, D., Melillo, R. M., Monaco, C., Visconti, R., Fenzi, G., Vecchio, G., Fusco, A., & Santoro, M. M. (2001) · PubMed · Cited by 71
Beldjord, C., Desclaux-Arramond, F., Raffin‐Sanson, M., Corvol, J., de Keyzer, Y., LUTON, J. P., Plouin, P., & BERTAGNA, X. Y. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608256 · Cited by 71
Jain, S. R., Watson, M. A., DeBenedetti, M. K., Hiraki, Y., Moley, J. F., & Milbrandt, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3801 · Cited by 71
Baumgartner-Parzer, S. M., Lang, R., Wagner, L., Heinze, G., Niederle, B., Kaserer, K., Waldhäusl, W., & Vierhapper, H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1278 · Cited by 70
Vaccinia as a vector for gene delivery
Guo, Z. S., & Bartlett, D. L. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.6.901 · Cited by 69
Thyroid Cancer Clinical Practice Guidelines in Oncology
Sherman, S. I., Angelos, P., Ball, D. W., Beenken, S. W., Byrd, D. R., Clark, O. H., Daniels, G. H., Dilawari, R. A., Ehya, H., Farrar, W. B., et al. (2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0021 · Cited by 69
Borkhardt, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00129-0 · Cited by 67
Collins, B., Chiappetta, G., Schneider, A. B., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8748 · Cited by 66
Melillo, R. M., Carlomagno, F., Vita, G. D., Formisano, P., Vecchio, G., Fusco, A., Billaud, M., & Santoro, M. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204049 · Cited by 66
Mutations in the RET protooncogene in sporadic pheochromocytomas
Lindor, N. M., Honchel, R., Khosla, S., & Thibodeau, S. N. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.2.7852530 · Cited by 61
Höppner, W. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.4.587 · Cited by 60
DEGROOT, J., Plaza-Menacho, I., Schepers, H., Drenth-Diephuis, L. J., Osinga, J. A. J., PLUKKER, J., Links, T. P., Eggen, B. J. L., & Hofstra, R. M. W. (2006) · Surgery · doi:10.1016/j.surg.2005.10.019 · Cited by 59
Self-citationCetta, F., Pelizzo, M., Curia, M. C., & Barbarisi, A. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65091-2 · Cited by 59
Design of growth factor antagonists with antiangiogenic and antitumor properties
Sebti, S. M., & Hamilton, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1204121 · Cited by 58
Kjær, S., & Ibáñez, C. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309772200 · Cited by 57
Multiple Signaling Pathways Converge on β-Catenin in Thyroid Cancer
Abbosh, P. H., & Nephew, K. P. (2005) · Thyroid · doi:10.1089/thy.2005.15.551 · Cited by 56
Kasprzak, L., Nolet, S., Gaboury, L. A., et al. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.784 · Cited by 55
Phay, J. E., Moley, J. F., & Lairmore, T. C. (2000) · Seminars in Surgical Oncology · Cited by 54
A RET double mutation in the germline of a kindred with FMTC
Bartsch, D. K., Hasse, C., Schug, C., et al. (2000) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2000-5806 · Cited by 53
Saenko, V., Rogounovitch, T., Shimizu‐Yoshida, Y., AIu, A., Lushnikov, E. F., Rumyantsev, P. O., Matsumoto, N., Nakashima, M., Meirmanov, S. K., Ohtsuru, A., et al. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(03)00056-3 · Cited by 52
Activation of BMK1 via Tyrosine 1062 in RET by GDNF and MEN2A Mutation
Hayashi, Y., Iwashita, T., Murakamai, H., Kato, Y., Kawai, K., Kurokawa, K., Tohnai, I., Ueda, M., & Takahashi, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4338 · Cited by 51
Kim, D. W., Hwang, J. H., Suh, J. M., Kim, H., Song, J. H., Hwang, E. S., Hwang, I. Y., Park, K. C., Chung, H. K., Kim, J., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0402 · Cited by 50
Miyagi, E., Braga‐Basaria, M., Hardy, E., Vasko, V. V., Burman, K. D., Jhiang, S. M., Saji, M., & Ringel, M. D. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20042 · Cited by 50
Differentiated Thyroid Carcinoma: A Polygenic Disease
Links, T. P., van Tol, K. M., Meerman, G. J. T., & de Vries, E. G. E. (2001) · Thyroid · doi:10.1089/10507250152740975 · Cited by 49
Self-citationKato, M., Takeda, K., Kawamoto, Y., Iwashita, T., Akhand, A. A., Senga, T., Yamamoto, M., Sobue, G., Hamaguchi, M., Takahashi, M., et al. (2002) · PubMed · Cited by 48
The RET proto-oncogene: a potential target for molecular cancer therapy
Pützer, B. M., & Drosten, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.06.002 · Cited by 47
Castellone, M. D., Celetti, A., Guarino, V., Cirafici, A. M., Basolo, F., Giannini, R., Médico, E., Kruhøffer, M., Orntoft, T. F., Curcio, F., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207322 · Cited by 46
Lesueur, F., Corbex, M. A., McKay, J. D., Lima, J. P., Soares, P., Griseri, P., Burgess, J., Ceccherini, I., Landolfi, S., Papotti, M. G., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.4.260 · Cited by 46
Carniti, C., Perego, C., Mondellini, P., Pierotti, M. A., & Bongarzone, I. (2003) · PubMed · Cited by 46
Lanzi, C., Cassinelli, G., Cuccuru, G., Zaffaroni, N., Supino, R., Vignati, S., Zanchi, C., Yamamoto, M., & Zunino, F. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-2381-8 · Cited by 45
van der Harst, E., de Krijger, R. R., Bruining, H. A., Lamberts, S. W. J., Bonjer, H. J., Dinjes, W. N. M., Proye, C. A. G., Koper, J. W., Bosman, F. T., Roth, J., et al. (1998) · International Journal of Cancer · Cited by 44
Rearrangements of RET and NTRK1 Tyrosine Kinase Receptors in Papillary Thyroid Carcinomas
Pierotti, M. A., Vigneri, P. G., & Bongarzone, I. (1998) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-46870-4_15 · Cited by 42
Puxeddu, E., Moretti, S., Giannico, A., Martinelli, M., Marino, C., Avenia, N., Cristofani, R., Farabi, R., Reboldi, G., Ribacchi, R., et al. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480505 · Cited by 41
Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow
Baloch, Z. W., & LiVolsi, V. A. (2005) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.5.4.573 · Cited by 38
Inhibition of Ret Oncogene Activity by the Protein Tyrosine Phosphatase SHP1
Hennige, A. M., Lammers, R., Höppner, W., Arlt, D., Strack, V., Teichmann, R. K., Machicao, F. E., Ullrich, A., Häring, H., & Kellerer, M. (2001) · Endocrinology · doi:10.1210/en.142.10.4441 · Cited by 35
Carlomagno, F., Melillo, R. M., Visconti, R., Salvatore, G., Vita, G. D., Lupoli, G., Yu, Y., Jing, S., Vecchio, G., Fusco, A., et al. (1998) · Endocrinology · doi:10.1210/endo.139.8.6124 · Cited by 35
Andreozzi, F., Melillo, R. M., Carlomagno, F., Oriente, F., Miele, C., Fiory, F., Santopietro, S., Castellone, M. D., Bèguinot, F., Santoro, M. M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206475 · Cited by 34
Melisi, D., Troiani, T., Damiano, V., Tortora, G., & Ciardiello, F. (2004) · Endocrine Related Cancer · doi:10.1677/erc.0.0110051 · Cited by 34
Nunes, A. B., Ezabella, M. C. L., Pereira, A. C., Krieger, J. E., & Toledo, S. P. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020345 · Cited by 32
Gimm, O., Dziema, H., Brown, J. A., Hoang‐Vu, C., Hinze, R., Dralle, H., Mulligan, L. M., & Eng, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204289 · Cited by 30
Yano, L., Shimura, M., Taniguchi, M., Hayashi, Y., Suzuki, T., Hatake, K., Takaku, F., & Ishizaka, Y. (2000) · Human Gene Therapy · doi:10.1089/10430340050015301 · Cited by 24
Yang, J., Lindahl, M., Lindholm, P., Virtanen, H., Coffey, E. T., Runeberg‐Roos, P., & Saarma, M. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.007 · Cited by 22
Stephens, L., Powell, N. G., Grubb, J., Jeremiah, S. J., Bethel, J., Demidchik, E. P., Ti, B., Tronko, M. D., & Thomas, G. A. (2005) · Thyroid · doi:10.1089/thy.2005.15.100 · Cited by 20
Knauf, J. A., Ouyang, B., Croyle, M., Kimura, E. T., & Fagin, J. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206829 · Cited by 18
Grap-2, a novel RET binding protein, is involved in RET mitogenic signaling
Ludwig, L., Kessler, H., Hoang‐Vu, C., Dralle, H., Adler, G., Boehm, B. O., & Schmid, R. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206517 · Cited by 12
Cited by
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Gharib, H., Papini, E., Garber, J. R., Duick, D. S., Harrell, R. M., Hegedus, L., Paschke, R., Valcavi, R., & Vitti, P. (2016) · Endocrine Practice · doi:10.4158/ep161208.gl · Cited by 1,272
Gharib, H., Papini, E., Paschke, R., Duick, D. S., Valcavi, R., Hegedüs, L., Vitti, P., Gharib, H., Papini, E., Paschke, R., et al. (2010) · Endocrine Practice · doi:10.4158/10024.gl · Cited by 1,088
Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
Nikiforova, M. N., Wald, A. I., Roy, S., Durso, M. B., & Nikiforov, Y. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2292 · Cited by 485
Metadata
- Authors
- de Groot, J. W. B., Links, T. P., Plukker, J. T. M., Lips, C. J. M., & Hofstra, R. M. W.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2006-07-18
- Volume
- 27
- Issue
- 5
- Pages
- 535-560
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2092228137
- Cited by
- 356
- References
- 194
- FWCI
- 14.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.